

Listing and evaluation of the results







1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 29 January 2021

Adviser:

221

Haemostasis 01 - PT, INR, aPTT







Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Prothrombintime (INR)	11		1.05	1.05	SV	0.809	1.29	0.0%	0	+	
	12		1.30	1.33	SV	1.02	1.64	-2.3%	-0,441	+	
Prothrombintime (Quick)	11	%	93.0	92.1	SV	70.9	113	1.0%	0,131	+	
	12		64.1	61.0	SV	47.0	75.0	5.1%	0,664	+	
aPTT	11	seconds	36.7	36.4	SV	29.8	43.0	0.8%	0,24	+	
	12		59.8	58.1	SV	47.6	68.6	2.9%	0,607	+	

** BRAVO **

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Testkit
Prothrombintime (INR)	11		1.05	1.00		BW	BW15	58
	12		1.30	1.00				
Prothrombintime (Quick)	11		93.0	1.00		BW	BW15	58
	12		64.1	1.00				
aPTT	11		36.7	1.00		BW	BW15	39
	12		59.8	1.00				

222

Haemostasis 02 - FIB, TZ, FSP

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
FDP screening	11	seconds	19.9	18.3	SV	16.6	20.0	8.7%	1,84	+	
	12		22.5	19.9	SV	18.1	21.7	13.1%	2,85	-	
Fibrinogen	11	mg/dl	240	246	SV	220	272	-2.3%	-0,445	+	
	12		393	345	SV	298	392	13.9%	2,04	-	
Thrombin Time	11	seconds	18.1	18.8	SV	17.4	20.2	-3.7%	-0,994	+	
	12		27.0	27.0	SV	23.7	30.3	0.0%	0	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Testkit
FDP screening	11		19.9	1.00	263	BW	BW15	14
	12		22.5	1.00				
Fibrinogen	11	mg/dl	240	1.00	260	BW	BW15	9999
	12		393	1.00				
Thrombin Time	11		18.1	1.00	263	BW	BW15	15
	12		27.0	1.00				

Listing and evaluation of the results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 29 January 2021

223

Haemostasis 03 - Factor II, V, VII,X

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Faktor II	11	%	90.2	91.7	SV	80.0	103	-1.6%	-0,256	+	
	12		25.0	22.8	SV	16.3	29.3	9.6%	0,673	+	
Faktor V	11	%	94.4	86.9	SV	74.1	99.7	8.6%	1,18	+	
	12		69.3	93.5	SV	59.9	127	-25.9%	-1,44	+	
Faktor VII	11	%	85.9	95.3	SV	83.5	107	-9.9%	-1,6	+	
	12		21.3	24.2	SV	18.5	29.9	-12.0%	-1,02	+	
Faktor X	11	%	91.5	92.2	SV	76.1	108	-0.8%	-0,087	+	
	12		12.5	11.7	SV	8.44	15.0	6.8%	0,491	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device
Faktor II	11		90.2	1.00	265	BW	BW15
	12		25.0	1.00			
Faktor V	11		94.4	1.00	265	BW	BW15
	12		69.3	1.00			
Faktor VII	11		85.9	1.00	265	BW	BW15
	12		21.3	1.00			
Faktor X	11		91.5	1.00	265	BW	BW15
	12		12.5	1.00			

224

Haemostasis 04 - Factor IX, XI, XII, XIII

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Faktor IX	11	%	107	93.4	SV	78.5	108	14.1%	1,77	+	
	12		70.3	59.1	SV	48.0	70.2	19.0%	2,02	-	
Faktor XI	11	%	96.5	89.1	SV	75.8	102	8.3%	1,11	+	
	12		71.9	67.9	SV	58.0	77.8	5.9%	0,808	+	
Faktor XII	11	%	110	96.9	SV	73.7	120	13.7%	1,15	+	
	12		80.4	73.1	SV	56.5	89.7	10.0%	0,881	+	
Faktor XIII	11	%	74.1	70.5	SV	60.9	80.1	5.1%	0,752	+	
	12		60.7	55.9	SV	48.8	63.0	8.6%	1,35	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device
Faktor IX	11		107	1.00	265	BW	BW15
	12		70.3	1.00			
Faktor XI	11		96.5	1.00	265	BW	BW15
	12		71.9	1.00			
Faktor XII	11		110	1.00	265	BW	BW15
	12		80.4	1.00			
Faktor XIII	11		74.1	1.00	257	BW	BW15
	12		60.7	1.00			

Listing and evaluation of the results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 29 January 2021

225

Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Antithrombin	11	%	88.0	91.4	SV	81.2	102	-3.7%	-0,665	+	
	12		85.3	87.1	SV	77.2	97.0	-2.1%	-0,365	+	
C1-Inhibitor	11	%	87.2	92.1	SV	82.6	102	-5.3%	-1,04	+	
	12		96.4	103	SV	89.8	116	-6.4%	-1	+	
free Protein S funct. (act.)	11	%	80.0	77.1	SV	61.8	92.4	3.8%	0,38	+	
	12		20.4	19.7	SV	11.0	28.4	3.6%	0,16	+	
free Protein S immun. (conc.)	11	%	90.0	89.9	SV	81.8	98.0	0.1%	0,025	+	
	12		33.5	32.7	SV	29.8	35.6	2.4%	0,559	+	
total Protein C	11	%	87.5	87.9	SV	79.0	96.8	-0.5%	-0,09	+	
	12		40.1	39.9	SV	32.6	47.2	0.5%	0,055	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device
Antithrombin	11		88.0	1.00	259	BW	BW15
	12		85.3	1.00			
C1-Inhibitor	11		87.2	1.00	257	BW	BW15
	12		96.4	1.00			
free Protein S funct. (act.)	11		80.0	1.00	263	BW	BW15
	12		20.4	1.00			
free Protein S immun. (conc.)	11		90.0	1.00	264	IL	IL03
	12		33.5	1.00			
total Protein C	11		87.5	1.00	257	BW	BW15
	12		40.1	1.00			

226

Haemostasis 06 - D-Dimer

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
D-Dimer (quant.)	11	µg/l	220		ET		<500		0,321	+	
	12		6690	6877	SV	5815	7939	-2.7%	-0,352	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Cut Off	Testkit
D-Dimer (quant.)	11	µg/l	220	1.00	264	BW	BW15		77
	12		6690	1.00					

Analyte	Sample	Method	Manufacturer	Device	Your specification(s)	Correct specification(s)	TV-Type	Meets criteria
D-Dimer (qual)	11				negative (1)	negative (1)	M	+
	12				negative (1)	positive (3)	M	-

Listing and evaluation of the results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 29 January 2021

227

Haemostasis 07 - Factor VIII, WF

Analyte	Sam-ple	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Faktor VIII akt.	11	%	106	100	SV	82.1	118	5.6%	0,625	+	
	12		0.890		ET		<=10.0		-0,592	+	
Willebrand Fact. Activity	11	%	74.2	70.1	SV	61.6	78.6	5.8%	0,96	+	
	12		<4.00		ET		<=15.0		0	+	
Willebrand Fact. Ag	11	%	98.3	96.0	ET	87.0	105	2.4%	0,484	+	
	12		<10.0		ET		<=15.0		0,96	+	
Willebrand Fact. CBA	11	%	59.5	68.3	SV	53.0	83.6	-12.9%	-1,15	+	
	12		1.45	1.72	SV	1.21	2.23	-15.7%	-1,06	+	

Analyte	Sam-ple	Your unit	Stated value	Conversion factor	Method	Manu-facturer	Device	Testkit
Faktor VIII akt.	11		106	1.00	265	BW	BW15	
	12		0.890	1.00				
Willebrand Fact. Activity	11		74.2	1.00	264	BW	BW15	101
	12		<4.00	1.00				
Willebrand Fact. Ag	11		98.3	1.00	264	BW	BW15	
	12		<10.0	1.00				
Willebrand Fact. CBA	11		59.5	1.00	9999	IL	IL05	231
	12		1.45	1.00				

506

Haemostasis 33 - Emicizumab

Analyte	Sam-ple	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
Emicizumab	11	µg/ml	31.6	30.0	SV	23.8	36.2	5.3%	0,516	+	
	12		76.3	69.9	SV	55.3	84.5	9.2%	0,877	+	

Analyte	Sam-ple	Your unit	Stated value	Conversion factor	Method	Manu-facturer	Device
Emicizumab	11	µg/ml	31.6	1.00	265	HO	IL03
	12		76.3	1.00			

Individual summary of results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 29 January 2021

221



Haemostasis 01 - PT, INR, aPTT

Prothrombintime (INR) (N = 392)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
TK.16, 51	11	0.993	0.765 - 1.22	0.993	9.67	10	90.0	90.0
	12	1.27	0.978 - 1.56	1.27	5.04	10	100	
STA Hepato-Prest Kap.Citratbl.	11	1.05	0.809 - 1.29	1.05	4.76	27	100	100
	12	1.10	0.847 - 1.35	1.10	4.82	27	100	
TK.45, 47 (1)	11	1.07	0.824 - 1.32	1.07	3.18	6		
	12	1.92	1.48 - 2.36	1.92	11.2	6		
TK.33, 162, 236	11	1.05	0.809 - 1.29	1.05	3.14	63	98.4	98.4
	12	1.29	0.993 - 1.59	1.29	3.10	63	100	
TK.43	11	0.974	0.750 - 1.20	0.974	2.36	94	100	98.9
	12	1.68	1.29 - 2.07	1.68	5.18	94	98.9	
Thromborel S	11	1.05	0.809 - 1.29	1.05	5.05	97	97.9	97.9
	12	1.33	1.02 - 1.64	1.33	5.11	97	100	
TK.36	11	1.07	0.824 - 1.32	1.07	3.27	26	100	100
	12	1.84	1.42 - 2.26	1.84	7.17	26	100	
Ganestin Plasma	11	1.00	0.770 - 1.23	1.00	5.80	11	100	100
	12	1.50	1.16 - 1.85	1.50	9.73	11	100	
TK.29, 49, 52 (1)	11	1.01	0.778 - 1.24	1.01	1.88	4		
	12	1.70	1.31 - 2.09	1.70	18.7	4		
TK.32 (1)	11	1.08	0.832 - 1.33	1.08	6.30	7		
	12	1.13	0.870 - 1.39	1.13	9.03	7		
Roche PT Screen	11	1.12	0.862 - 1.38	1.12	3.21	12	100	100
	12	1.43	1.10 - 1.76	1.43	4.06	12	100	
Stago STA NeoPTimal	11	1.06	0.816 - 1.30	1.06	2.64	35	100	94.3
	12	1.76	1.36 - 2.16	1.76	6.14	35	94.3	



(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 98%



Prothrombintime (Quick) (% , N = 392)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Roche PT Screen	11	90.5	69.7 - 111	90.5	6.63	12	100	100
	12	62.6	48.2 - 77.0	62.6	4.94	12	100	
TK.31-32	11	91.4	70.4 - 112	91.4	9.67	33	97.0	97.0
	12	82.5	63.5 - 101	82.5	10.3	33	97.0	
TK.36	11	89.8	69.1 - 110	89.8	4.88	26	100	100
	12	44.4	34.2 - 54.6	44.4	8.06	26	100	
TK.16, 29, 34, 49, 51	11	100	77.0 - 123	100	12.0	23	95.7	95.7
	12	60.1	46.3 - 73.9	60.1	13.3	23	95.7	
TK.33, 236	11	90.9	70.0 - 112	90.9	5.18	59	94.9	94.9
	12	58.7	45.2 - 72.2	58.7	4.51	59	96.6	
TK.43	11	105	80.9 - 129	105	3.56	94	100	96.8
	12	46.3	35.7 - 56.9	46.3	9.16	94	96.8	
TK.45, 52 (1)	11	92.5	71.2 - 114	92.5	7.09	6		
	12	39.5	30.4 - 48.6	39.5	20.5	6		
Thromborel S	11	92.1	70.9 - 113	92.1	7.44	98	96.9	95.9
	12	61.0	47.0 - 75.0	61.0	7.66	98	96.9	
TK.47, 235	11	91.4	70.4 - 112	91.4	3.38	39	100	92.3
	12	46.2	35.6 - 56.8	46.2	8.48	39	92.3	





Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
Owrens PT (1)	11	130	100 - 160	130	8.00	2		
	12	72.8	56.1 - 89.5	72.8	1.65	2		


(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 95,9%

aPTT (seconds, N = 342)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
TK.9-10, 238	11	25.8	21.2 - 30.4	25.8	4.65	53	96.2	96.2		
	12	39.7	32.6 - 46.8	39.7	5.29	53	96.2			
Hemosil APTT-SP liquid.	11	25.8	21.2 - 30.4	25.8	1.99	15	100	100		
	12	47.3	38.8 - 55.8	47.3	2.77	15	100			
Pathromtin-SL	11	36.4	29.8 - 43.0	36.4	3.43	92	97.8	96.7		
	12	58.1	47.6 - 68.6	58.1	4.82	92	96.7			
Roche aPTT MedS	11	35.9	29.4 - 42.4	35.9	4.15	12	100	100		
	12	60.0	49.2 - 70.8	60.0	4.42	12	100			
Hemosil APTT lyophilized Silica	11	33.5	27.5 - 39.5	33.5	3.52	79	97.5	97.5		
	12	44.1	36.2 - 52.0	44.1	3.06	79	98.7			
TK.17, 28, 41	11	32.8	26.9 - 38.7	32.8	2.38	29	100	100		
	12	49.3	40.4 - 58.2	49.3	2.86	29	100			
TK.8, 48, 50	11	30.8	25.3 - 36.3	30.8	3.51	32	93.8	87.5		
	12	42.7	35.0 - 50.4	42.7	4.59	32	90.6			
TK.79, 239	11	32.3	26.5 - 38.1	32.3	5.76	12	100	100		
	12	56.6	46.4 - 66.8	56.6	4.31	12	100			
TK.40, 42	11	29.7	24.4 - 35.0	29.7	4.18	12	100	91.7		
	12	46.9	38.5 - 55.3	46.9	7.42	12	91.7			
absence / incorrect coding (1)	11	21.5	17.6 - 25.4	21.5	35.0	6				
	12	29.1	23.9 - 34.3	29.1	12.6	6				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 94,7%




222

Haemostasis 02 - FIB, TZ, FSP

FDP screening (seconds, N = 39)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
G.BW18-BW19, TK.14 (1)	11	21.0	19.7 - 22.3	21.0	3.04	7				
	12	21.7	19.1 - 24.3	21.7	6.04	7				
Batroxobin	11	18.3	16.6 - 20.0	18.3	4.75	19	100	94.7		
	12	19.9	18.1 - 21.7	19.9	4.58	19	94.7			
Reptilase	11	17.2	13.9 - 20.5	17.2	9.65	13	92.3	92.3		
	12	18.8	16.5 - 21.1	18.8	6.01	13	100			

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.


Rate of success: 92,3%



Fibrinogen (mg/dl, N = 166)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
Claus method, undiluted Plasma	11	246	220 - 272	246	5.20	43	88.4	76.7		
	12	345	298 - 392	345	6.84	43	83.7			
M.261, R.BW	11	239	216 - 262	239	4.73	30	93.3	90.0		
	12	326	294 - 358	326	4.91	30	93.3			
M.261, R.ST	11	249	225 - 273	249	4.86	26	96.2	96.2		
	12	352	306 - 398	352	6.53	26	100			
M.63, 261	11	235	195 - 275	235	8.47	61	95.1	91.8		
	12	314	259 - 369	314	8.79	61	93.4			
Turbidimetry (1)	11	262	262 - 262	262	0.000	1				
	12	342	342 - 342	342	0.000	1				
M.256, TK.43 (1)	11	250	205 - 295	250	9.08	3				
	12	316	281 - 351	316	5.57	3				
derived, other testkits (1)	11	201	179 - 223	201	5.57	2				
	12	322	306 - 338	322	2.49	2				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.


Rate of success: 88,6%



Thrombin Time (seconds, N = 121)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
BC-Thrombin Reag. Lösen 5ml	11	18.8	17.4 - 20.2	18.8	3.74	24	100	79.2		
	12	27.0	23.7 - 30.3	27.0	6.07	24	79.2			
Hemosil Thrombin (mit 5ml gelöst)	11	17.6	15.8 - 19.4	17.6	5.02	30	90.0	86.7		
	12	16.6	15.0 - 18.2	16.6	4.70	30	90.0			
TK.55, 125	11	14.6	13.4 - 15.8	14.6	3.99	12	100	100		
	12	46.1	33.4 - 58.8	46.1	13.7	12	100			
TK.86, 155 (1)	11	17.3	14.5 - 20.1	17.3	8.03	4				
	12	18.9	15.6 - 22.2	18.9	8.73	4				
Test-Thrombin (5ml)	11	19.2	17.0 - 21.4	19.2	5.73	26	100	92.3		
	12	21.9	19.4 - 24.4	21.9	5.62	26	92.3			
STA-Thrombin	11	17.3	16.6 - 18.0	17.3	2.12	20	85.0	85.0		
	12	19.3	18.2 - 20.4	19.3	2.83	20	90.0			
absence / incorrect coding (1)	11	17.4	12.6 - 22.2	17.4	13.7	5				
	12	19.5	15.7 - 23.3	19.5	9.85	5				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 84,3%







Faktor II (% , N = 61)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.265, R.IL	11	92.1	80.5 - 104	92.1	6.30	16	87.5	87.5		
	12	19.8	15.9 - 23.7	19.8	9.75	16	100			
M.265, R.BW, HY, SI	11	91.7	80.0 - 103	91.7	6.39	35	100	100		
	12	22.8	16.3 - 29.3	22.8	14.3	35	100			
M.265, R.ST	11	87.2	81.1 - 93.3	87.2	3.47	9	88.9	88.9		
	12	21.9	17.4 - 26.4	21.9	10.2	9	100			
M.265, R.GL (1)	11	106	106 - 106	106	0.000	1				
	12	27.4	27.4 - 27.4	27.4	0.000	1				



(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 95,1%





Faktor V (% , N = 70)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.265, R.IL	11	85.1	72.7 - 97.5	85.1	7.27	19	100	89.5		
	12	79.8	60.3 - 99.3	79.8	12.2	19	89.5			
M.265, R.BW, GL, SI	11	86.9	74.1 - 99.7	86.9	7.34	42	92.9	90.5		
	12	93.5	59.9 - 127	93.5	18.0	42	95.2			
M.265, R.ST	11	87.1	74.1 - 100	87.1	7.47	9	88.9	88.9		
	12	78.9	66.0 - 91.8	78.9	8.17	9	100			

Rate of success: 90%





Faktor VII (% , N = 65)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
M.265, R.IL	11	91.9	80.1	-	104	91.9	6.44	18	94.4	94.4
	12	19.1	14.6	-	23.6	19.1	11.7	18	100	
M.265, R.ST	11	94.4	76.5	-	112	94.4	9.48	9	88.9	88.9
	12	30.6	22.3	-	38.9	30.6	13.6	9	100	
M.265, R.BW, GL, SI	11	95.3	83.5	-	107	95.3	6.18	38	94.7	86.8
	12	24.2	18.5	-	29.9	24.2	11.7	38	89.5	

Rate of success: 89,2%



Faktor X (% , N = 60)										
Collective	Sample	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
M.265, R.IL	11	84.4	72.4	-	96.4	84.4	7.10	17	100	88.2
	12	11.1	9.24	-	13.0	11.1	8.39	17	88.2	
M.265, R.BW, GL, SI	11	92.2	76.1	-	108	92.2	8.72	34	100	94.1
	12	11.7	8.44	-	15.0	11.7	13.9	34	94.1	
M.265, R.ST	11	87.0	77.9	-	96.1	87.0	5.25	9	100	100
	12	11.2	8.10	-	14.3	11.2	13.8	9	100	

Rate of success: 93,3%







Haemostasis 04 - Factor IX, XI, XII, XIII

Faktor IX (% , N = 71)										
Collective	Sam-ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.265, R.IL	11	78.4	67.0 - 89.8	78.4	7.30	22	90.9	86.4		
M.265, R.BW	12	50.0	39.9 - 60.1	50.0	10.1	22	95.5			
M.265, R.BW	11	93.4	78.5 - 108	93.4	7.99	35	97.1	91.4		
M.265, R.BW	12	59.1	48.0 - 70.2	59.1	9.37	35	91.4			
M.265, R.ST, M.257	11	95.4	71.0 - 120	95.4	12.8	14	100	92.9		
M.265, R.ST, M.257	12	61.0	45.4 - 76.6	61.0	12.8	14	92.9			



Rate of success: 90,1%



Faktor XI (% , N = 67)										
Collective	Sam-ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.265, R.IL	11	79.4	71.4 - 87.4	79.4	5.01	18	94.4	94.4		
M.265, R.IL	12	63.0	55.1 - 70.9	63.0	6.29	18	100			
M.265, R.BW, GL, SI	11	89.1	75.8 - 102	89.1	7.47	42	95.2	95.2		
M.265, R.BW, GL, SI	12	67.9	58.0 - 77.8	67.9	7.29	42	97.6			
M.265, R.ST (1)	11	98.8	69.2 - 128	98.8	15.0	7				
M.265, R.ST (1)	12	76.6	51.4 - 102	76.6	16.4	7				

Rate of success: 95,5%


(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.



Faktor XII (% , N = 59)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
M.265, R.IL	11	93.6	81.6	-	106	93.6	6.40	18	88.9	83.3
	12	73.2	57.7	-	88.7	73.2	10.6	18	88.9	
M.265, R.BW, GL, SI	11	96.9	73.7	-	120	96.9	12.0	34	100	97.1
	12	73.1	56.5	-	89.7	73.1	11.3	34	97.1	
M.265, R.ST (1)	11	103	83.9	-	122	103	9.27	7		
	12	80.7	63.1	-	98.3	80.7	10.9	7		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.



Rate of success: 93,2%



Faktor XIII (% , N = 72)										
Collective	Sam- ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
M.257, R.BW, SI	11	70.5	60.9	-	80.1	70.5	6.79	44	90.9	88.6
	12	55.9	48.8	-	63.0	55.9	6.37	44	95.5	
M.264, R.IL	11	75.3	66.0	-	84.6	75.3	6.19	16	93.8	87.5
	12	57.9	45.8	-	70.0	57.9	10.5	16	93.8	
Turbidimetry: latex-enhancend	11	93.0	66.0	-	120	93.0	14.5	9	100	100
	12	73.6	48.0	-	99.2	73.6	17.4	9	100	
absence / incorrect coding (1)	11	74.4	58.6	-	90.2	74.4	10.6	3		
	12	59.8	51.5	-	68.1	59.8	6.92	3		

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 86,1%






Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor

Antithrombin (% , N = 170)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.258, R.BW, SI	11	90.0	84.1 - 95.9	90.0	3.30	26	88.5	88.5		
	12	86.6	78.0 - 95.2	86.6	4.97	26	96.2			
M.258, R.RO	11	90.3	79.1 - 101	90.3	6.18	9	100	100		
	12	87.5	78.1 - 96.9	87.5	5.39	9	100			
M.258, R.ST	11	92.7	81.0 - 104	92.7	6.31	24	95.8	95.8		
	12	88.2	75.7 - 101	88.2	7.11	24	95.8			
M.63, R.APT (1)	11	306	306 - 306	306	0.000	1				
	12	371	371 - 371	371	0.000	1				
M.259, R.IL, WF	11	95.8	85.1 - 107	95.8	5.59	50	96.0	94.0		
	12	91.5	81.5 - 102	91.5	5.48	50	96.0			
GR, M.259, R.BW, ST, HY, SI, M.63	11	91.4	81.2 - 102	91.4	5.59	59	96.6	93.2		
	12	87.1	77.2 - 97.0	87.1	5.66	59	96.6			
absence / incorrect coding (1)	11	85.0	85.0 - 85.0	85.0	0.000	1				
	12	81.0	81.0 - 81.0	81.0	0.000	1				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.


Rate of success: 92,9%



C1-Inhibitor (% , N = 54)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.257, R.BW	11	92.1	82.6 - 102	92.1	5.14	39	94.9	92.3		
	12	103	89.8 - 116	103	6.39	39	94.9			
chromogenic assay	11	93.8	80.8 - 107	93.8	6.91	14	100	92.9		
	12	105	88.0 - 122	105	8.10	14				
Immunological test (EIA) (1)	11	117	117 - 117	117	0.000	1				
	12	117	117 - 117	117	0.000	1				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.


Rate of success: 90,7%



free Protein S funct. (act.) (% , N = 69)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.263, R.IL, WF	11	78.3	68.2 - 88.4	78.3	6.48	23	95.7	91.3		
	12	26.4	18.0 - 34.8	26.4	15.8	23	95.7			
M.263, R.BW, SI	11	77.1	61.8 - 92.4	77.1	9.90	23	91.3	87.0		
	12	19.7	11.0 - 28.4	19.7	22.2	23	91.3			
M.263, R.ST	11	76.9	61.9 - 91.9	76.9	9.73	13	100	84.6		
	12		- <20.0	9.45	94.9	13	84.6			
M.263, R.HY (1)	11	73.6	64.6 - 82.6	73.6	6.11	6				
	12	32.3	10.0 - 55.0	44.2	69.0	6				
M.263, R.COA (1)	11	68.7	57.0 - 80.4	68.7	8.52	2				
	12	53.1	0.000 - 107	53.1	51.0	2				
absence / incorrect coding (1)	11	82.8	56.4 - 109	82.8	15.9	2				
	12	23.0	0.000 - 80.8	23.0	126	2				


(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 85,5%



free Protein S immun. (conc.) (% , N = 118)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.264, R.IL, WF	11	89.9	81.8 - 98.0	89.9	4.48	35	94.3	88.6		
	12	32.7	29.8 - 35.6	32.7	4.37	35	91.4			
M.264, R.BW, RO, SI	11	81.4	75.8 - 87.0	81.4	3.42	55	94.5	89.1		
	12	36.2	32.8 - 39.6	36.2	4.72	55	92.7			
M.264, R.CX, HY, ST	11	82.2	70.3 - 94.1	82.2	7.26	18	94.4	83.3		
	12	36.4	32.6 - 40.2	36.4	5.19	18	88.9			
M.63-64	11	85.0	72.5 - 97.5	85.0	7.33	10	90.0	90.0		
	12	34.8	27.7 - 41.9	34.8	10.2	10	100			


Rate of success: 88,1%



total Protein C (% , N = 143)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.263, R.BW (1)	11	91.5	84.2 - 98.8	91.5	3.98	5				
	12	25.0	10.0 - 40.0	23.8	68.5	5				
M.263, R.IL, ST (1)	11	86.4	74.9 - 97.9	86.4	6.67	7				
	12	9.68	2.48 - 16.9	9.68	37.2	7				
M.257, R.IL, WF	11	87.7	81.9 - 93.5	87.7	3.28	43	90.7	76.7		
	12	50.0	24.8 - 75.2	50.0	25.2	43	83.7			
M.257, R.BW, SI	11	87.9	79.0 - 96.8	87.9	5.05	63	93.7	90.5		
	12	39.9	32.6 - 47.2	39.9	9.15	63	95.2			
M.257, R.ST	11	84.1	75.8 - 92.4	84.1	4.92	18	100	100		
	12	37.4	33.4 - 41.4	37.4	5.32	18	100			
chromogenic assay (1)	11	85.8	77.6 - 94.0	85.8	4.79	5				
	12	38.7	23.5 - 53.9	38.7	19.6	5				
M.63-64 (1)	11	77.6	63.0 - 92.2	77.6	9.41	2				
	12	35.9	33.0 - 38.8	35.9	4.01	2				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 88,1%






226

Haemostasis 06 - D-Dimer

D-Dimer (quant.) (µg/l, N = 264)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
BioMérieux Vidas	(1) 11	221	108 - 334	221	25.5	4				
	12	6374	3986 - 8762	6374	18.7	4				
TK.70, 93, 149	11		- <500	291	17.5	36	94.4	94.4		
	12	6121	4469 - 7773	6121	13.5	36	94.4			
D-Dimer HS500	11	291	186 - 396	291	18.0	36	94.4	86.1		
	12	6261	5623 - 6899	6261	5.10	36	88.9			
OSR60135 D Dimer	(1) 11	165	112 - 218	165	16.1	6				
	12	4670	4150 - 5190	4670	5.57	6				
D-Dimer Tinaquant	11	239	88.0 - 390	239	31.6	20	95.0	90.0		
	12	4707	3981 - 5433	4707	7.71	20	95.0			
D Dimer FS (Diasys)	(1) 11	370	370 - 370	370	0.000	1				
	12	2130	2130 - 2130	2130	0.000	1				
Innovance D-Dimer	11		- <500	210	14.9	98	99.0	91.8		
	12	6877	5815 - 7939	6877	7.72	98	91.8			
D-Dimer HS	11	117	55.0 - 179	117	26.5	8	100	87.5		
	12	2283	1751 - 2815	2283	11.7	8	87.5			
TK.73, 254	(1) 11	110	10.0 - 210	89.4	73.2	5				
	12	2414	1454 - 3374	2414	19.9	5				
TK.92, 160, 190	11		- <300	170	46.1	9	100	100		
	12	2775	1425 - 4125	2775	24.3	9	100			
G.RO09, RO58	11	95.2	38.4 - 152	95.2	29.8	20	100	100		
	12	3862	1660 - 6064	3862	28.5	20	100			
G.RA09, MIT01	11	248	57.4 - 439	248	38.4	17	94.1	76.5		
	12	4982	3962 - 6002	4982	10.2	17	82.4			
absence / incorrect coding	(1) 11	155	81.8 - 228	155	23.6	4				
	12	4010	1270 - 6750	4010	34.2	4				

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 90,2%



226

Haemostasis 06 - D-Dimer

D-Dimer (qual) (N = 126, Rate of success: 96,8%)

Sample 11

Collective	negative (1)	positive (3)	total
all results	125 ●	1	126

Sample 12

Collective	negative (1)	positive (3)	total
all results	4	122 ●	126

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective




Haemostasis 07 - Factor VIII, WF

Faktor VIII akt. (% , N = 145)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.257, R.BW	(1)	11	92.6	63.6 - 122	92.6	15.7	6			
		12		- <=10.0	5.30		110	6		
chromogenic assay	(1)	11	88.2	68.2 - 108	88.2	11.3	7			
		12		- <=1.00	0.875		47.9	7		
M.265, R.IL, WF		11	81.5	64.4 - 98.6	81.5	10.5	39	87.2	87.2	
		12		- <=5.00	1.53		33.9	39	97.4	
M.265, R.BG, BW, SI		11	100	82.1 - 118	100	8.96	73	95.9	94.5	
		12		- <=10.0	1.50		68.7	73	98.6	
M.265, R.RO, ST		11	95.5	79.0 - 112	95.5	8.62	19	100	100	
		12		- <=3.00	1.57		38.3	19	100	
absence / incorrect coding	(1)	11	99.0	99.0 - 99.0	99.0	0.000	1			
		12	1.00	1.00 - 1.00	1.00	0.000	1			


(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 91,7%



Willebrand Fact. Activity (% , N = 97)										
Collective	Sample	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
Innovance vWF Ac		11	70.1	61.6 - 78.6	70.1	6.09	67	95.5	94.0	
		12		- <=15.0	4.00		0.000	67	98.5	
TK.102, 257		11	79.3	66.0 - 92.6	79.3	8.36	30	93.3	86.7	
		12		- <=15.0	7.02		53.3	30	93.3	

Rate of success: 91,8%





Willebrand Fact. Ag (% , N = 119)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
M.63, 339, R.HO, IL, TC (1)	11	99.2	89.2 - 109	99.2	5.05	6		
	12	1.84	0.758 - 2.92	1.84	29.4	6		
M.264, R.IL, WF	11	101	93.8 - 108	101	3.58	33	97.0	97.0
	12		- <=8.50	3.83	40.2	33	100	
M.264, R.BG, BW, SI, , M.63	11	96.0	87.0 - 105	96.6	4.92	67	97.0	97.0
	12		- <=15.0	5.91	72.1	67	100	
M.264, R.ST, TB	11	100	92.5 - 107	100	3.73	13	100	100
	12		- <=3.00	3.00	0.000	13	100	

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.



Rate of success: 96,6%


Willebrand Fact. CBA (% , N = 38)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
TK.165, 177, 234 (1)	11	83.0	61.2 - 105	83.0	13.1	6		
	12		- <=10.0	4.88	75.4	6		
HemosIL AcuStar vWF:CB	11	68.3	53.0 - 83.6	68.3	11.2	17	100	94.1
	12	1.72	1.21 - 2.23	1.72	14.8	17	94.1	
TECHNOZYM vWF: CBA Elisa Kit	11	94.0	63.0 - 125	94.0	16.5	15	86.7	73.3
	12	2.50	1.00 - 5.00	2.51	66.5	15	80.0	

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 84,2%






506

Haemostasis 33 - Emicizumab

Emicizumab (µg/ml, N = 16)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
M.257, 265	11	30.0	23.8 - 36.2	30.0	10.3	16	93.8	93.8		
	12	69.9	55.3 - 84.5	69.9	10.4	16	100	100		

Rate of success: 93,8%



EXAMPLE